Comparison · NCT03439072-d6792084
G-Pen vs Lilly Glucagon: Number of Subjects With Relief of Neuroglycopenic Symptoms
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. G-Pen vs Lilly Glucagon: Number of Subjects With Relief of Neuroglycopenic Symptoms. Trial comparisons, record NCT03439072-d6792084. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03439072-d6792084
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.974 | 0.909 | 0.993 | wilson | |
| Risk in group 2 | 0.987 | 0.931 | 0.998 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0135 | -0.079 | 0.0459 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.986 | 0.943 | 1.03 | log | |
| Odds ratio, group 1 over group 2 | 0.481 | 0.0427 | 5.41 | log | |
| Number needed to treat, for one fewer participant with the outcome on G-Pen than on Lilly Glucagon | 74.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | G-Pen | G-Pen: 1 mg subcutaneous injection of G-Pen (glucagon injection) administered via auto-injector | 74 | 76 | OG000 |
| Group 2 | Lilly Glucagon | Lilly Glucagon: 1 mg subcutaneous injection of Lilly Glucagon (glucagon injection \[RNDA Origin\]) | 77 | 78 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Subjects With Relief of Neuroglycopenic Symptoms
- Description
- Clearance of all neuroglycopenic symptoms of hypoglycemia within 30 minutes after receiving glucagon. Four symptoms were assessed: dizziness, blurred vision, difficulty in thinking and faintness.
- Time frame
- 0 to 30 minutes post dose
- Population
- Intent to treat analysis population
Source ClinicalTrials.gov
Trial
- Title
- G-Pen™ Compared to Lilly Glucagon for Hypoglycemia Rescue in Adults With Type 1 Diabetes
- NCT number
- NCT03439072
- Phases
- PHASE3
- Conditions
- Insulin Hypoglycemia, Type 1 Diabetes Mellitus, Severe Hypoglycemia
- Interventions
- G-Pen, Lilly Glucagon
- Lead sponsor
- Xeris Pharmaceuticals
- Results first posted
- 2019-05-30
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03439072?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03439072-d6792084